ecancerTV/SABCS 2015 interview: Javier Cortes discusses efficacy and gene expression results from eribulin neoadjuvant study

At the recent annual San Antonio Breast Cancer Symposium (SABCS), 8 – 12 December, San Antonio, USA, the ecancerTV team caught up with Javier Cortés to discuss latest findings from the phase II SOLTI1007 study: a prospective, open-label, single-arm, exploratory pharmacogenomic study of single agent eribuilin as neoadjuvant treatment for stage I-II HER2-negative metastatic breast cancer.

The results were presented during the Symposium at Poster Session 3, Thursday 10 December: Prognostic and Predictive Factors: Response Predictions — Biomarkers and Other Factors.

To view the filmed interview and find out more please click here.

Related Posts

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.